highly significantp < 10 −9
The Kruskal–Wallis test confirmed highly significant global heterogeneity (H = 94.31, p < 10 −9 ).
The Kruskal–Wallis test confirmed highly significant global heterogeneity (H = 94.31, p < 10 −9 ).
Within the diabetic cohorts, glimepiride+bisoprolol alone had a decreasing trend (−0.66 percentage points from baseline to week 11; Wilcoxon p = 0.004) and was trending towards healthy levels.